Mogamulizumab, an Anti-CCR4 Antibody, Targets Human T-Lymphotropic Virus Type 1–infected CD8+and CD4+T Cells to Treat Associated Myelopathy
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Human T-lymphotropic virus type 1 (HTLV-1) can cause chronic spinal cord inflammation, known as HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). Since CD4(+)CCR4(+) T cells are the main HTLV-1 reservoir, we evaluated the defucosylated humanized anti-CCR4 antibody mogamulizumab as a treatment for HAM/TSP. METHODS: We assessed the effects of mogamulizumab on peripheral blood mononuclear cells from 11 patients with HAM/TSP. We also studied how CD8(+) T cells, namely CD8(+) CCR4(+) T cells and cytotoxic T lymphocytes, are involved in HTLV-1 infection and HAM/TSP pathogenesis and how they would be affected by mogamulizumab. RESULTS: Mogamulizumab effectively reduced the HTLV-1 proviral load (56.4% mean reduction at a minimum effective concentration of 0.01 µg/mL), spontaneous proliferation, and production of proinflammatory cytokines, including interferon γ (IFN-γ). Like CD4(+)CCR4(+) T cells, CD8(+)CCR4(+) T cells from patients with HAM/TSP exhibited high proviral loads and spontaneous IFN-γ production, unlike their CCR4(-) counterparts. CD8(+)CCR4(+) T cells from patients with HAM/TSP contained more IFN-γ-expressing cells and fewer interleukin 4-expressing cells than those from healthy donors. Notably, Tax-specific cytotoxic T lymphocytes that may help control the HTLV-1 infection were overwhelmingly CCR4(-). CONCLUSIONS: We determined that CD8(+)CCR4(+) T cells and CD4(+)CCR4(+) T cells are prime therapeutic targets for treating HAM/TSP and propose mogamulizumab as a new treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Joshi, N. S., Cui, W., Chandele, A., Lee, H. K., Urso, D. R., Hagman, J., Gapin, L., & Kaech, S. M. (2007) · Immunity · doi:10.1016/j.immuni.2007.07.010 · Cited by 1,861 · cited 1×
“the chronic viral infection [38–40].”
Nagai, M., Usuku, K., Matsumoto, W., Kodama, D., Takenouchi, N., Moritoyo, T., Hashiguchi, S., Ichinose, M., Bangham, C. R., Izumo, S., et al. (1998) · Journal of Neurovirology · doi:10.3109/13550289809114225 · Cited by 694 · cited 1×
“It is well established that high proviral load is associated with the onset and progression of HAM/TSP [7, 33], as well as with the development of ATL [34].”
BackgroundHuman T-lymphotropic virus 1: recent knowledge about an ancient infection
Verdonck, K., González, E., Van Dooren, S., Vandamme, A.-M., Vanham, G., & Gotuzzo, E. (2007) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(07)70081-6 · Cited by 661 · cited 1×
“Human T-lymphotropic virus type 1 (HTLV-1) infects 10–20 million people worldwide, causing HTLV1–associated myelopathy/tropical spastic paraparesis (HAM/TSP) and adult T-cell leukemia/lymphoma (ATL) in a small fraction of infected individuals [1–3].”
BackgroundIzumo, S., Goto, I., Itoyama, Y., Okajima, T., Watanabe, S., Kuroda, Y., Araki, S., Mori, M., Nagataki, M., Matsukura, S., et al. (1996) · Neurology · doi:10.1212/wnl.46.4.1016 · Cited by 164
Therapeutic trials in 200 patients with HTLV-Iassociated myelopathy/tropical spastic paraparesis
Nakagawa, M., Nakahara, K., Maruyama, Y., Kawabata, M., Higuchi, I., Kubota, H., Izumo, S., Arimura, K., & Osame, M. (1996) · Journal of Neurovirology · doi:10.3109/13550289609146899 · Cited by 150
Yamano, Y., Araya, N., Sato, T., Utsunomiya, A., Azakami, K., Hasegawa, D., Izumi, T., Fujita, H., Aratani, S., Yagishita, N., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006517 · Cited by 140
Self-citationTaylor, G. P., Goon, P., Furukawa, Y., Green, H., Barfield, A., Mosley, A., Nose, H., Babiker, A., Rudge, P., Usuku, K., et al. (2006) · Retrovirology · doi:10.1186/1742-4690-3-63 · Cited by 117 · cited 2×
“clinical trials [8, 9].”
Background
Cited by
HTLV-1-associated myelopathy/tropical spastic paraparesis
Bangham, C. R. M., Araujo, A., Yamano, Y., & Taylor, G. P. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.12 · Cited by 279
Self-citationFutsch, N., Mahieux, R., & Dutartre, H. (2017) · Viruses · doi:10.3390/v10010001 · Cited by 155
“Interestingly, mogamulizumab effectively reduces HTLV-1 proviral load, spontaneous proliferation of CCR4-positive CD4+ and CD8+ T-cells, as well as pro-inflammatory cytokines production [199].”
BackgroundMogamulizumab (Anti-CCR4) in HTLV-1-Associated Myelopathy
Sato, T., Coler-Reilly, A. L. G., Yagishita, N., Araya, N., Inoue, E., Furuta, R., Watanabe, T., Uchimaru, K., Matsuoka, M., Matsumoto, N., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1704827 · Cited by 113
Self-citationHuman T-cell leukemia virus type 1 infects multiple lineage hematopoietic cells in vivo
Furuta, R., Yasunaga, J.-I., Miura, M., Sugata, K., Saito, A., Akari, H., Ueno, T., Takenouchi, N., Fujisawa, J.-I., Koh, K.-R., et al. (2017) · PLOS Pathogens · doi:10.1371/journal.ppat.1006722 · Cited by 83
Coler-Reilly, A. L. G., Sato, T., Matsuzaki, T., Nakagawa, M., Niino, M., Nagai, M., Nakamura, T., Takenouchi, N., Araya, N., Yagishita, N., et al. (2017) · Neurotherapeutics · doi:10.1007/s13311-017-0533-z · Cited by 39
Self-citation
Metadata
- Authors
- Yamauchi, J., Coler-Reilly, A., Sato, T., Araya, N., Yagishita, N., Ando, H., Kunitomo, Y., Takahashi, K., Tanaka, Y., Shibagaki, Y., Nishioka, K., Nakajima, T., Hasegawa, Y., Utsunomiya, A., Kimura, K., & Yamano, Y.
- Venue
- Journal of Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-08-07
- Volume
- 211
- Issue
- 2
- Pages
- 238-248
- ISSN
- 0022-1899 (ISSN-L)
- 1537-6613
- OpenAlex
- W2116147619
- Cited by
- 41
- References
- 7
- FWCI
- 2.46
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mogamulizumab, an Anti-CCR4 Antibody, Targets Human T-Lymphotropic Virus Type 1–infected CD8+and CD4+T Cells to Treat Associated Myelopathy. https://app.cochat.ai/papers/10.1093/infdis/jiu438
- The paper
- Yamauchi, J., Coler-Reilly, A., Sato, T., Araya, N., Yagishita, N., Ando, H., Kunitomo, Y., Takahashi, K., Tanaka, Y., Shibagaki, Y., Nishioka, K., Nakajima, T., Hasegawa, Y., Utsunomiya, A., Kimura, K., & Yamano, Y. (2015). Mogamulizumab, an Anti-CCR4 Antibody, Targets Human T-Lymphotropic Virus Type 1–infected CD8+and CD4+T Cells to Treat Associated Myelopathy. Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiu438
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.